JAMA Author Interviews – Details, episodes & analysis

Transfusion strategy for patients with acute brain injury, telehealth care, acute kidney injury after cardiac surgery, and weaning ventilatory support are the topics of 4 trials published in JAMA and presented at the 2024 European Society of Intensive Care Medicine meeting. JAMA Associate Editor Christopher Seymour, MD, MSc, joins Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, to discuss.

Related Content:

• Shifting Balance of the Risk-Benefit of Restrictive Transfusion Strategies in Neurocritically Ill Patients—Is Less Still More?
• Evaluating Complex Technological Innovations in Critical Care—Current Challenges and Future Directions
• Impact of Adsorptive Blood Purification on Kidney Outcomes
• Ventilator Weaning Strategies—Managing Interaction Between Randomized Treatments
• Restrictive vs Liberal Transfusion Strategy in Patients With Acute Brain Injury
• Effect of Tele-ICU on Clinical Outcomes of Critically Ill Patients
• Extracorporeal Blood Purification and Acute Kidney Injury in Cardiac Surgery
• Frequency of Screening and Spontaneous Breathing Trial Techniques

Gastric cancer is a leading cause of cancer death globally. Chronic H pylori infection is the primary cause of gastric cancer, responsible for at least 80% of the new cases. Constanza Camargo, PhD, of the National Cancer Institute joins JAMA Associate Editor John M. Inadomi, MD, to discuss co-testing with FIT and H pylori stool antigen to help prevent gastric cancer.

Related Content:

• Fecal Immunochemical Test and Helicobacter pylori Stool Antigen Co-Testing
• Screening for Helicobacter pylori to Prevent Gastric Cancer

Ten percent of US adolescents use e-cigarettes, and many want to quit. However, evidence on the effectiveness of vaping cessation interventions is lacking. Amanda L. Graham, PhD, of the Truth Initiative discusses with JAMA Senior Editor Tracy Lieu, MD, MPH, how a tailored, interactive text message intervention increased vaping cessation among adolescents recruited via social media channels.

Related Content:

• A Vaping Cessation Text Message Program for Adolescent E-Cigarette Users
• Supporting Adolescents’ Desire to Quit E-Cigarettes
• What Are E-Cigarettes?
• Variability in Constituents of E-Cigarette Products Containing Nicotine Analogues
• E-Cigarette Use in Adults
• Controversial FDA Decision Authorizes Menthol-Flavored E-Cigarettes Despite Risks to Youth
• Vaping in Youth
• E-Cigarette Use in Adolescents and Adults—A JAMA Collection

Electronic health records (EHRs) hold great promise to assist clinicians, but current versions are less user-friendly than ideal. JAMA Associate Editor Tracy Lieu, MD, MPH, spoke with Kevin B. Johnson, MD, MS, University of Pennsylvania, and William W. Stead, MD, Vanderbilt University Medical Center, about how to improve EHRs to protect cognitive attention and optimize their potential to provide cognitive support to health care professionals.

Related Content:

• Making Electronic Health Records Both SAFER and SMARTER

In this Author Interview, JAMA Deputy Editor Gregory Curfman, MD, discusses the state of coronary artery bypass surgery in 2022 with E. Magnus Ohman, MD, from Duke University. The conversation emphasizes methods to preserve patency of saphenous vein bypass grafts, the subject of an article in the August 9, 2022, issue of JAMA. Dr Ohman wrote the accompanying Editorial.

Related Content:

• Association of Dual Antiplatelet Therapy With Ticagrelor With Vein Graft Failure After Coronary Artery Bypass Graft Surgery
• Balancing the Risks and Benefits of Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery

On August 3, 2022, the US Department of Health and Human Services released 2 major reports in response to a presidential memo calling for a whole-of-government response to the SARS-CoV-2 sequelae known as “Long COVID." JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, discusses these new reports and the research and support needed to address this pervasive health concern with HHS Assistant Secretary for Health Rachel Levine, MD. Recorded July 29, 2022.

Related Content:

• Addressing the Long-term Effects of COVID-19
• Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers
• Long COVID: The US Federal Response (Video)

Interview with Lori Pbert, PhD, USPSTF member and coauthor of Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Cardiovascular Disease Risk Factors: US Preventive Services Task Force Recommendation Statement. Hosted by JAMA Senior Editor Kristin L. Walter, MD, MS.

Related Content:

• Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Known Cardiovascular Disease Risk Factors
• Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Cardiovascular Disease Risk Factors
• Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity to Prevent CVD in Adults Without Risk Factors
• Implications of the New Recommendation on Behavioral Counseling Interventions to Promote Healthy Eating and Physical Activity
• Improving Behavioral Counseling for Primary Cardiovascular Disease Prevention
• Updated USPSTF Recommendations for Behavioral Counseling Interventions

Exercise limitation is a cardinal manifestation of heart failure with reduced ejection fraction (HFrEF), but it is not consistently improved by any of the current guideline-directed medical therapies. JAMA Deputy Editor Gregory Curfman, MD, discusses whether omecamtiv mecarbil can improve peak exercise capacity in patients with HFrEF with Gregory D. Lewis, MD, from Massachusetts General Hospital, and Mark H. Drazner, MD, MSc, from University of Texas Southwestern Medical Center.

Related Content:

• Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial
• Omecamtiv Mecarbil as a Therapy for Heart Failure With Low Ejection Fraction

JAMA Associate Editor Preeti Malani, MD, MSJ, discusses the transmission, diagnosis, and treatment of monkeypox and the 2022 outbreak with Jeannette Guarner, MD, and Carlos del Rio, MD, both of the Division of Infectious Diseases at Emory University’s School of Medicine. Read Transcript

Related Content:

• Monkeypox in 2022—What Clinicians Need to Know

• What Is Monkeypox?

• What to Know About Monkeypox

• Global Monkeypox Outbreaks Spur Drug Research for the Neglected Disease

Patient safety is a national priority, but adverse events during hospitalization are hard to track and whether progress has been made over the past decade is unknown. JAMA Associate Editor Karen E. Joynt Maddox, MD, MPH, Washington University School of Medicine, discusses recent findings demonstrating decreases in hospital chart-abstracted adverse events and what’s next in patient safety in the wake of COVID-19, with Mark Metersky, MD, University of Connecticut Health Center, and Peter Pronovost, MD, PhD, University Hospitals, Shaker Heights, Ohio.

Related Content:

• Trends in Adverse Event Rates in Hospitalized Patients, 2010-2019

• Improvements in Hospital Adverse Event Rates: Achieving Statistically Significant and Clinically Meaningful Results